COMPANY RESEARCHShanghai Junshi Biosciences Co., Ltd.
Shanghai Junshi Biosciences is a China-based innovative biopharmaceutical company focused on discovering and developing therapeutic antibodies and other medicines. Its work includes immuno-oncology, autoimmune and inflammatory diseases, as well as selected infectious-disease programs. The company is associated with the development of toripalimab, an anti-PD-1 antibody, and maintains broader research platforms for antibody engineering and targeted therapies. Junshi has shares listed on the Shanghai Stock Exchange STAR Market under 688180 and on the Hong Kong Stock Exchange under 1877. Both listings refer to the same issuer.
Company at a glance
Corporate information
- Company entity
- Shanghai Junshi Biosciences Co., Ltd.
- Headquarters / principal office
- China
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.junshipharma.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
SSE STAR: 688180 HKEX: 01877
monoclonal antibodies · immune checkpoint therapy · antibody-drug conjugates
oncology · immunology · infectious diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Shanghai Junshi Biosciences is a China-based innovative biopharmaceutical company focused on discovering and developing therapeutic antibodies and other medicines. Its work includes immuno-oncology, autoimmune and inflammatory diseases, as well as selected infectious-disease programs. The company is associated with the development of toripalimab, an anti-PD-1 antibody, and maintains broader research platforms for antibody engineering and targeted therapies. Junshi has shares listed on the Shanghai Stock Exchange STAR Market under 688180 and on the Hong Kong Stock Exchange under 1877. Both listings refer to the same issuer.
Business, technology & evidence
- SecuritiesSSE STAR: 688180 / HKEX: 01877
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Shanghai Junshi Biosciences Co., Ltd. ↗Shanghai Junshi Biosciences Co., Ltd. ·
- Official issuer and R&D disclosure · Shanghai Junshi Biosciences Co., Ltd. ↗Shanghai Junshi Biosciences Co., Ltd. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.